Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose study of HP-3180 in healthy Japanese adult females
jRCT2031250597Phase 1Active, not recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HP-3180 (4 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetics and Safety. Started Jan 2026; status: active, not recruiting.
02
Drugs
HP-3180
Beyond the preview
Go deeper on jRCT2031250597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250597.